TLX.AX stock trades at A$11.10 intraday on 15 Jan 2026 as Telix Pharmaceuticals (TLX.AX, ASX) heads into an earnings update scheduled for 20 Jan 2026. Investors will focus on clinical progress for TLX591 and TLX250, revenue per share trends, and whether guidance or commercial updates narrow the gap to prior highs. Volume is elevated at 2,049,443.00 shares versus average 1,777,974.00, signalling firm trader interest. This earnings spotlight explains the key metrics, risks and a Meyka AI model forecast ahead of the report.
TLX.AX stock earnings timetable and expectations
Telix lists an official earnings announcement for 20 Jan 2026; intraday traders on 15 Jan 2026 are positioning ahead of that release. Analysts will watch revenue, EPS and commentary on TLX591 Phase 3 and TLX250 Phase 3 commercialization timing. Expect management to address commercial rollouts, margin trends and any near-term regulatory milestones that could alter the revenue outlook.
TLX.AX stock financials and valuation
Telix reports EPS A$0.04 and a top-line market valuation of A$3757241176.00 (A$3.76B). The quoted PE is 277.50 and price-to-sales is 3.16, highlighting a premium valuation versus many healthcare peers. Current ratios show liquidity at 1.33 and debt-to-equity near 0.99, which implies leverage that investors should track if commercial cash flow softens.
Clinical pipeline and revenue drivers for TLX.AX stock
Telix’s main commercial catalysts are TLX591 (prostate cancer) and TLX250 (renal cancer) — both carry Phase III readouts or regulatory actions that could change revenue pacing. Pipeline success would push longer-term revenue per share growth, while setbacks would likely pressure sentiment and the rich valuation multiple. Institutional investors and partners remain a driver of capital and distribution reach for these assets.
Technical and trading snapshot for TLX.AX stock
Intraday price range is A$10.94–A$11.24 with the stock trading A$11.10 and volume 2,049,443.00, a relative volume of 1.15. Technical indicators show RSI 29.09 (oversold) and ADX 42.99 (strong trend), while the 50-day average is A$13.19 and 200-day average is A$19.06, suggesting the stock is below key moving averages. Traders should watch volatility (ATR 0.49) and the Bollinger lower band at A$10.18 for intraday support.
Analyst views, news flow and risks for TLX.AX stock
Consensus remains mixed: several buys and holds sit alongside at least one sell, and average price targets from some sources previously clustered around A$21.00. Recent headlines include a J.P. Morgan presentation and media coverage of legal and trading moves that add short-term noise; see coverage from Seeking Alpha and MarketBeat. Key risks are trial delays, commercialization execution and potential litigation or reimbursement setbacks.
Meyka AI grade and TLX.AX stock forecast
Meyka AI rates TLX.AX with a score of 68.51 out of 100 — Grade B, HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of A$13.28, a monthly target A$16.02, and a three-year estimate A$6.10. Forecasts are model-based projections and not guarantees. For live metrics see the Meyka TLX page.
Final Thoughts
TLX.AX stock opens this intraday session at A$11.10 with heightened volume and a clear calendar catalyst: the company’s earnings update on 20 Jan 2026. The immediate market debate will centre on revenue growth and pipeline news for TLX591 and TLX250, which can materially shift sentiment given the company’s premium valuation (PE 277.50) and thin free cash flow yield. Technically the name is oversold (RSI 29.09) and trading below both the 50-day (A$13.19) and 200-day (A$19.06) averages, so expect volatility around guidance and trial updates. Meyka AI’s forecast model projects a yearly price of A$13.28, implying an upside of 19.62% versus the current A$11.10. Forecasts are model-based projections and not guarantees. Traders should weigh clinical binary risk, existing leverage and analyst views before positioning ahead of the release. Meyka AI provides AI-powered market analysis to help frame these risks and opportunities.
FAQs
When does Telix report earnings and why does it matter for TLX.AX stock
Telix has an earnings announcement set for 20 Jan 2026. The report matters because management commentary on TLX591 and TLX250 development and commercial rollouts can shift revenue guidance and the premium valuation of TLX.AX stock.
What are the top financial figures to watch in the TLX.AX earnings report
Watch revenue, EPS A$0.04, operating cash flow per share and any guidance on commercial uptake. Valuation metrics like PE 277.50 and price-to-sales 3.16 will frame investor reactions to the results.
How does Meyka AI view TLX.AX stock ahead of earnings
Meyka AI rates TLX.AX 68.51/100 — Grade B, HOLD and projects a yearly price of A$13.28. The model flags pipeline catalysts but notes high valuation and leverage as risks. Forecasts are model-based and not guarantees.
What are the main investment risks for TLX.AX stock right now
Primary risks are Phase III trial setbacks, slower-than-expected commercial adoption, reimbursement challenges and litigation headlines. These can compress the premium valuation and raise volatility for TLX.AX stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)